Rani Therapeutics appoints Michelle Gilson to Board of Directors, as Audit Committee chair

Rani Therapeutics Holdings, Inc.

Michelle Gilson appointed to Board effective August 1, 2026; also named chair of Audit Committee.
Gilson, 34, was CFO of Arcellx until its acquisition by Gilead in April 2026.
Prior roles include Senior Biotechnology Equity Research Analyst at Canaccord Genuity (Managing Director) and earlier at Jefferies, Nomura, Oppenheimer, Goldman Sachs.
She will receive compensation per company's Non-Employee Director Compensation Policy; standard indemnification agreement.
No arrangements, family relationships, or material interests in transactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.